vs
Side-by-side financial comparison of PLAYSTUDIOS, Inc. (MYPS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $55.4M, roughly 1.9× PLAYSTUDIOS, Inc.). PLAYSTUDIOS, Inc. runs the higher net margin — -24.7% vs -29.4%, a 4.7% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -18.3%). PLAYSTUDIOS, Inc. produced more free cash flow last quarter ($3.6M vs $-34.8M).
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
MYPS vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $55.4M | $103.7M |
| Net Profit | $-13.7M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -17.7% | -31.7% |
| Net Margin | -24.7% | -29.4% |
| Revenue YoY | -18.3% | 16.9% |
| Net Profit YoY | 38.9% | 3.4% |
| EPS (diluted) | $-0.12 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.4M | $103.7M | ||
| Q3 25 | $57.6M | — | ||
| Q2 25 | $59.3M | — | ||
| Q1 25 | $62.7M | — | ||
| Q4 24 | $67.8M | — | ||
| Q3 24 | $71.2M | — | ||
| Q2 24 | $72.6M | — | ||
| Q1 24 | $77.8M | — |
| Q4 25 | $-13.7M | $-30.5M | ||
| Q3 25 | $-9.1M | — | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-2.9M | — | ||
| Q4 24 | $-22.4M | — | ||
| Q3 24 | $-3.1M | — | ||
| Q2 24 | $-2.6M | — | ||
| Q1 24 | $-567.0K | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -17.7% | -31.7% | ||
| Q3 25 | -13.6% | — | ||
| Q2 25 | -5.9% | — | ||
| Q1 25 | -4.4% | — | ||
| Q4 24 | -33.1% | — | ||
| Q3 24 | -6.7% | — | ||
| Q2 24 | -5.5% | — | ||
| Q1 24 | -2.2% | — |
| Q4 25 | -24.7% | -29.4% | ||
| Q3 25 | -15.8% | — | ||
| Q2 25 | -5.0% | — | ||
| Q1 25 | -4.6% | — | ||
| Q4 24 | -33.1% | — | ||
| Q3 24 | -4.3% | — | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | -0.7% | — |
| Q4 25 | $-0.12 | $-0.50 | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.02 | — | ||
| Q1 25 | $-0.02 | — | ||
| Q4 24 | $-0.18 | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.9M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $227.9M | $456.1M |
| Total Assets | $290.6M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $104.9M | $197.9M | ||
| Q3 25 | $106.3M | — | ||
| Q2 25 | $112.9M | — | ||
| Q1 25 | $107.1M | — | ||
| Q4 24 | $109.2M | — | ||
| Q3 24 | $105.2M | — | ||
| Q2 24 | $106.3M | — | ||
| Q1 24 | $127.0M | — |
| Q4 25 | $227.9M | $456.1M | ||
| Q3 25 | $238.9M | — | ||
| Q2 25 | $245.3M | — | ||
| Q1 25 | $244.1M | — | ||
| Q4 24 | $244.7M | — | ||
| Q3 24 | $265.2M | — | ||
| Q2 24 | $263.6M | — | ||
| Q1 24 | $288.4M | — |
| Q4 25 | $290.6M | $638.1M | ||
| Q3 25 | $299.2M | — | ||
| Q2 25 | $316.2M | — | ||
| Q1 25 | $313.8M | — | ||
| Q4 24 | $323.0M | — | ||
| Q3 24 | $330.6M | — | ||
| Q2 24 | $333.4M | — | ||
| Q1 24 | $357.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $-24.8M |
| Free Cash FlowOCF − Capex | $3.6M | $-34.8M |
| FCF MarginFCF / Revenue | 6.5% | -33.5% |
| Capex IntensityCapex / Revenue | 0.2% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $25.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $-24.8M | ||
| Q3 25 | $5.7M | — | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $3.3M | — | ||
| Q4 24 | $11.6M | — | ||
| Q3 24 | $14.6M | — | ||
| Q2 24 | $14.5M | — | ||
| Q1 24 | $5.0M | — |
| Q4 25 | $3.6M | $-34.8M | ||
| Q3 25 | $5.4M | — | ||
| Q2 25 | $13.2M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $11.5M | — | ||
| Q3 24 | $13.9M | — | ||
| Q2 24 | $12.8M | — | ||
| Q1 24 | $3.6M | — |
| Q4 25 | 6.5% | -33.5% | ||
| Q3 25 | 9.3% | — | ||
| Q2 25 | 22.3% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 17.6% | — | ||
| Q1 24 | 4.6% | — |
| Q4 25 | 0.2% | 9.6% | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MYPS
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
